

ESG Vision - Vistin Pharma

Environment, Social and Governance

2021 - 2024



OUR “NO HARM VISION”

Vistin Pharma long term vision is to have no negative impact on environment, people and local community by our presence

Vistin is a «green» and environmentally friendly pharmaceutical company with a “no harm” vision and “front runner” ambition

Our goal is to double our manufacturing capacity without increased environmental impact on water, air and soil

Environmental and Operational Sustainability

«Vistin Pharma are proud of our sustainability achievements, our track record of deliverables and ongoing ESG focus» *Kjell-Erik Nordby, CEO*

«We believe our ESG initiatives create added value for our customers supply chain footprint as well as being a good local corporate citizen by having very low impact on environment, people and local community”
Vegard Heggem, VP Operations

“Our operational sustainability improves the material flows and financial success of our customers by ensuring a steady and continuous delivery of high-quality product from Vistin Pharma without supply constraints”
Magnus Tolleshaug, Commercial Director

ESG achievements and 2021-2024 projects

ESG achievements and initiatives at Vistin

Actively taking part in the circular economy as waste generated at Vistin is sent to approved incineration plant where the energy is reused as heat media for local communities and industry

Vistin has, since 2017, been part of a national program for surveillance of industrial impact on fjords and effluents. Surveillance program and ecotoxicology test confirm that Vistin do not impact the effluent negatively

Shifted from oil-based energy to hydro powered energy to reduce carbon footprint

Recover and reuse > 95% of our solvents used in the manufacture of metformin

Vistin is initiating a project with aim to reduce the water consumption in the plant by 90% through recycling

Investing approx. €1mill in a technology development project and establish a new state of the art VOC to reduce the emission of solvents (butanol) to air by > 95%

Invested in a 2nd barrier, discharge tank of wastewater to avoid any uncontrolled discharge local community waste plant. Result: no discharge to the local community sewer above the strict permits set by the Norwegian Environmental Authorities during the last 4 years

Started a technology project where distillation will be fractionated into components that can be used as raw materials for other companies. Waste becomes raw material

Implemented internal recycling of waste in our manufacturing plant and focus on reusable gear instead of one-time equipment

No registered work-related personnel injuries for more than four years. Sick leave (%) is currently lower than the Norwegian pharmaceutical industry average

Well-balanced gender equality and age distribution and a policy to ensure all employees have equal opportunities based on skills and potential

ESG Projects 2021-2024

Reduce emission of VOC to air by 90% by 2021

- Installation and start up in 2021
- Total investment cost, approx. 1,0 MEUR
- Innovative technology developed with local engineering company

Reduce water consumption in the plant by 90% through recycling by 2022

- May be used as source for energy supply to local Kragerø Industrial Area
- Total investment cost approx. 1,2MEUR

Reduce pharmaceutical content in waste

- Estimated investment cost > 1,5 MEUR

No increase in discharge to sea from doubled production capacity

- Innovative process design in expansion project performed

Program for monitoring effluents in the environment and living species

- Cost for five year program approx. 0,9MEUR.

Change of packaging material in DC granulate product

- Change final packaging material from fibre drums to polyethylene plastic bags
- Will reduce environmental footprint in fabrication of material, transport and customer waste generation

Reduction of plant energy consumption

- Optimizing of steam and condensate system by heat integration

Operational Sustainability achievements

- Vistin has over the last couple of years invested more than €4 mill in the Fikkjebakke plant to reduce operational risks and improve product quality and performance. These investments include among the following a) a new closed and fully automated packaging line, b) a 2nd reactor for the synthesis of metformin HCl, c) a new QC lab and new HPLC and GC equipment
- Vistin is currently investing €10 mill in establishing a 2nd metformin HCl production line in the FB plant. The objective is to a) double the current production capacity and be able to grow with our customers and the ever growing metformin market and b) significantly reduce the risk of potential production stops due to machine failures etc
- Vistin has worked in closed cooperation with the Norwegian and Indian government and health authorities to secure supply of critical raw materials during the Covid-19 pandemic as well as procedures to reduce the risk of Covid-19 infected employees. We are proud to inform that we have succeeded in both these objectives. The plant has been running at full capacity throughout the Covid-19 pandemic and as of today we have had no Covid-19 infected employees in Vistin Pharma
- Vistin has during 2020 invested in building a “Covid-19” extra 3 months security stock of key raw materials DCDA/DMA
- Vistin has done a tremendous work to analyse and document the nitrosamine content in more than 600 batches of metformin HCl. We have received very positive results from the analyses showing that our product does not contain detectable contents of nitrosamine. This project has so far costed Vistin approx. €400.000,-
- Vistin will invest in an own R&D lab in 2021-2022 to have even more resources focusing on process optimisation and other improvement projects